« Kos seeks FDA OK for Niaspan caplets (Pharmaceutical Business Review) | Main | FDA Approvals - Kensey Nash Receives FDA 510(k) Clearance For TriActiv FX(R) Embolic »

FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration


FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration
Lucentis is the first treatment which, when dosed monthly, can maintain the vision of more than 90 percent of patients with this type of AMD.
 

©2006 FDA-News.com. All rights reserved.